Texas Biomed Launches $2 Million Fund to Combat Tuberculosis through Innovative Research

Texas Biomed Launches Tuberculosis Innovation Fund

In a groundbreaking initiative, the Texas Biomedical Research Institute has announced the establishment of a $2 million Tuberculosis Innovation and Technology Fund. This significant philanthropic investment is poised to enhance research efforts aimed at combating tuberculosis (TB), which tragically remains one of the deadliest infectious diseases globally, claiming over a million lives each year.

Dr. Larry Schlesinger, the President and CEO of Texas Biomed and a well-respected figure in TB research, emphasized the importance of this fund: "This is a powerful investment in the future of TB research. The fund allows us to strengthen our scientific capabilities and brings us closer to more effective prevention and treatment for a disease that affects millions worldwide. We are deeply grateful for this vote of confidence in our mission."

The fund aims to attract and retain top scientific talent in a field known for its competitiveness and also to equip researchers with cutting-edge technologies necessary for innovative studies. These advanced tools will provide unprecedented insights into the mechanisms of TB infection, its progression, and the interactions at a cellular level.

Sarah Fortune, an esteemed expert from the Harvard T.H. Chan School of Public Health, noted that this investment is revolutionary for global TB prevention efforts. She stated, "This philanthropic investment in TB research at Texas Biomedical Research Institute will be transformative in the fight against tuberculosis. Sustained innovation is essential to help end the global TB epidemic. This partnership is a testament to how public-private collaborations can drive significant progress in public health."

Among the advanced technologies acquired with the funding are the Akoya Phenocycler system and the Emulate Orb and Zoe Culture module system. These organ-on-a-chip technologies enable rapid identification of biomarkers and testing of vaccines and therapeutics. Such New Approach Methodologies (NAMs) are essential for expeditiously advancing drug development while ensuring safety and efficacy for potential new medicines.

Despite common perceptions of TB as an illness of the past or primarily affecting developing nations, the reality is starkly different. Texas faces significant challenges with TB, consistently reporting some of the highest case numbers in the U.S. In fact, in 2024, the state documented 1,270 TB cases, reflecting a concerning 16% increase since 2022.

Texas Biomed also plays a pivotal role in educating future researchers through its NIH-funded Interdisciplinary NexGen TB Research Advancement Center (IN-TRAC). This initiative pools expertise and resources from various institutions, including UTHealth Houston School of Public Health Brownsville, UT Rio Grande Valley, and The Heartland National TB Center, further strengthening collaborative efforts to tackle challenging TB cases.

Sara Wise, Vice President of Development at Texas Biomed, expressed gratitude for the community's support in propelling the institute into its new era of discovery. She highlighted the transformative nature of the fund as a testament to the community's commitment to scientific advancement and global health improvement.

For those interested in supporting Texas Biomed's mission and contributing to the ongoing battle against TB, further information regarding giving opportunities is available through their official channels. This strategic investment not only promises to enhance TB research at Texas Biomed but also embodies a collective commitment to improving health globally, aiming to eradicate one of history's most persistent and deadly diseases.